Immunotep innovative tumor immunotherapy imp-321 obtains positive mid-term clinical data

February 24, 2020 / Meitong news agency / -- wuxibiology, the world's leading open biopharmaceutical technology platform company, Immutep, a strategic partner of 2269 HK), recently released the interim data of tacti-002 in the ongoing phase II clinical trial of soluble LAG-3 protein ("efti" or "imp321"), a major candidate product, and Yaoming biological expressed congratulations on its positive clinical research results Immunotep is a global biotechnology company dedicated to developing innovative immunotherapies for cancer and autoimmune diseases At the beginning of its establishment in 2010, the company had only four employees In 2013, it became the first European customer of YaoMing bio, and has successfully promoted the clinical trials of imp321 in Europe and the United States under the enabling of YaoMing bio's excellent biopharmaceutical capability and technology platform In November 2016, the two sides signed a memorandum of understanding to establish a strategic partnership for imp321 R & D and production The published clinical trial data of tacti-002 is based on the first-line treatment of non-small cell lung cancer (NSCLC) with eftiagimodalpha combined with keytruda ® (pembrolizumab) The results of this study showed that the overall response rate (ORR) of the combination therapy was 47%, while that of the single drug therapy of pabolizumab was only about 20% Compared with the use of pabolizumab alone, LAG-3 protein can activate antigen-presenting cells (APC) to aggregate T cells, which may produce stronger antitumor effect "The results of this study are very encouraging," said Marc Voigt, chief executive of immunotep As an important partner of this innovative tumor immunotherapy, Yaoming biology has contributed a wealth of professional knowledge and effectively guaranteed the quality of the project With the continuous progress of clinical trials, we will continue to maintain close cooperation and vigorously promote the global clinical development of imp321 with the help of the efficient and reliable production technology platform of YaoMing biology " "Congratulations on the exciting research results of immunotep," said Dr Chen Zhisheng, CEO of YaoMing biology "We are honored to empower the global innovative biotechnology company represented by immunotep to rapidly promote the whole process from concept to commercial production of biological drugs Yaoming biology will continue to provide biopharmaceuticals that meet global quality standards through a sound and powerful global supply chain network, accelerate the clinical development process of imp321, an innovative tumor immunotherapy, and benefit patients " About immunotep immunotep is an active global biotechnology company, leading in the research and development of lag-3-related immunotherapy for cancer and autoimmune diseases Immutep is committed to using advanced technology and expertise to provide innovative treatment solutions for patients and maximize shareholder value Immutep is listed on the Australian Stock Exchange (Stock Code: IMM) and the US NASDAQ (Stock Code: IMMP) As the main candidate product of immunotep, eftilagimodalpha ("efti" or "imp321") is a soluble LAG-3 protein (lag-3ig) based on LAG-3 immune regulation mechanism, which plays an important role in regulating T cell immune response Efti's ongoing clinical trials include: AIPAC, a phase IIB clinical trial, as chemoimmunotherapy for metastatic breast cancer; tacti002, a phase II clinical trial in cooperation with methadone, to evaluate the efficacy of efti and keytruda ® (pembrolizumab, anti-PD-1 therapy) combined therapy in different solid tumors (clinicaltrials.gov registration number: nct03625323); and German Merck / Pfizer cooperated in phase I clinical trial insight-004 to evaluate the efficacy of efti combined with avelumab (clinical trials Gov Registration No.: nct03252938) and a phase I clinical trial tacti Mel (clinical trials Gov Registration No.: nct02676869) for the treatment of metastatic melanoma Immunotep's large pharmaceutical partners are developing other LAG-3 products, including antibodies, that regulate autoimmune and cancer immune responses Immunotep is also developing a LAG-3 agonist (imp761) for autoimmune diseases As a Hong Kong listed company, Yaoming bio (Stock Code: 2269 HK) is the world's leading open, integrated bio pharmaceutical capability and technology enabling platform The company provides a full range of end-to-end R & D services for global biopharmaceutical companies and biotechnology companies, helps anyone and any company to discover, develop and produce biopharmaceuticals, realizes the whole process from concept to commercial production, accelerates the global R & D process of biopharmaceuticals, reduces the cost of research and development, and benefits patients As of June 30, 2019, there are 224 comprehensive projects developed on the platform, including 106 in the preclinical research stage, 102 in the early clinical (phase I, phase II), 15 in the late clinical (phase III) and 1 in the commercial production stage It is estimated that by 2022, the total capacity of the company's planned biopharmaceutical production bases in China, Ireland, Singapore and the United States will exceed 280000 liters, which will effectively ensure that the company will provide customers with biopharmaceuticals that meet global quality standards through a sound and strong global supply chain network 37